- Zura Bio has two tibulizumab Phase 2 trials fully enrolled.
- FDA cleared a third tibulizumab Phase 2 PMR study for Zura Bio.
- Company disclosed $187.7 million in cash, expecting operational runway to extend through at least 2028.
Tuesday, October 27, 2026
Zura Bio Q3: non-GAAP EPS -0.20, revenue $0, beat estimates as tibulizumab Phase 2 programs advance
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.